We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00673686
First Posted: May 7, 2008
Last Update Posted: October 13, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
  Purpose
In this study a comparison was made on the influence of missing pills on follicular ripening. By missing a given number of pills, an effect on "contraceptive robustness" of the two investigated contraceptive pills was measured by ultrasound comparison of follicular size and other parameters which indicate how far ovulation might be.

Condition Intervention Phase
Contraceptives, Oral Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) Drug: Yasminelle (SH T 00186 D) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Center, Double-blind, Randomized Study to Compare the Effect of SH T 00186 D on Follicular Development in a 24-day Regimen Versus a 21-day Regimen in Healthy Female Volunteers

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Hoogland scores in cycles 2 and 3 [ Time Frame: Treatment cycles 2 and 3 (treatment weeks 5-12) ]

Secondary Outcome Measures:
  • Follicle size [ Time Frame: Treatment cycles 2 and 3 (treatment weeks 5-12 ]
  • Hormone levels of progesterone, estradiol, luteinizing hormone, follicle stimulating hormone [ Time Frame: Treatment cycles 2 and 3 (treatment weeks 5-12 ]
  • Endometrial thickness [ Time Frame: Treatment cycles 2 and 3 (treatment weeks 5-12 ]
  • Cervical mucus [ Time Frame: Treatment cycles 2 and 3 (treatment weeks 5-12 ]

Enrollment: 105
Study Start Date: May 2004
Study Completion Date: February 2005
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 2 Drug: Yasminelle (SH T 00186 D)
SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
Experimental: Arm 1 Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy women aged 18 to 35 years inclusive (smokers aged up to 30 years inclusive)
  • No contraindications for combined oral contraceptive (COC) use
  • Follicular diameter of greater-equal than 15 mm on visit 6 (admission to treatment), or an observed ovulation during pretreatment cycle Exclusion Criteria:
  • Pregnancy or lactation- Substantial overweight, i.e., body mass index (BMI) > 30,
  • Known hypersensitivity to any of the study drug ingredients
  • Any disease that may worsen under hormonal treatment or might interfere with the conduct of the study, or the interpretation of the results
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00673686


Locations
Netherlands
Groningen, Netherlands, 9713 GZ
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00673686     History of Changes
Other Study ID Numbers: 91377
308382
First Submitted: May 6, 2008
First Posted: May 7, 2008
Last Update Posted: October 13, 2014
Last Verified: October 2014

Keywords provided by Bayer:
Oral contraceptive
Ovulation
Missing pills
Intake compliance
Cycle control

Additional relevant MeSH terms:
Drospirenone and ethinyl estradiol combination
Reproductive Control Agents
Physiological Effects of Drugs